I hope you are right, true I did not factor in the the R& D rebate, due in April - sorry, I was going off the quarterly where it showed only 3.3 quarters of cash on hand this is based on the quarterly cash flow and expenditure divided into cash on hand.
I would expect the out goings to be higher in the next few quarters due to MPL manufacturing, tablet manufacturing etc and the covid trial - I think the funding from MND will cover the trial plus some of the mpl / tablets.
Of course and increase in Epichem revenue / profit would also help in putting off a cr
Ann: Appendix 4C and Quarterly Update, page-54
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $80.22M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.5¢ | $210.6K | 1.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 274938 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 15000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |